Q3 EPS Estimates for Legend Biotech Raised by HC Wainwright

Posted by George Bondi on Oct 16th, 2026

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) – HC Wainwright raised their Q3 2026 earnings per share estimates for Legend Biotech in a report released on Wednesday, October 14th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of $0.02 per share for the quarter, up from their prior estimate of ($0.02). HC Wainwright has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($0.09) per share. HC Wainwright also issued estimates for Legend Biotech’s FY2026 earnings at $0.00 EPS.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.07 by $0.02. Legend Biotech had a negative return on equity of 8.71% and a negative net margin of 7.21%. The business had revenue of $387.50 million for the quarter, compared to the consensus estimate of $355.96 million. During the same period in the previous year, the company posted $0.03 earnings per share. The company’s revenue for the quarter was up 51.9% compared to the same quarter last year.

Several other equities analysts have also issued reports on the company. Oppenheimer lowered Legend Biotech from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $75.00 to $40.00 in a research report on Wednesday, August 12th. Morgan Stanley set a $65.00 price target on shares of Legend Biotech in a research note on Friday, September 4th. JPMorgan Chase & Co. cut their price objective on shares of Legend Biotech from $35.00 to $33.00 and set a “neutral” rating on the stock in a research report on Friday, October 9th. UBS Group restated a “buy” rating and set a $65.00 price objective on shares of Legend Biotech in a research note on Monday, September 28th. Finally, Royal Bank Of Canada decreased their target price on shares of Legend Biotech from $58.00 to $56.00 and set an “outperform” rating for the company in a report on Thursday, October 8th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Legend Biotech currently has a consensus rating of “Moderate Buy” and an average price target of $55.07.

Check Out Our Latest Stock Analysis on Legend Biotech

Legend Biotech Price Performance

NASDAQ LEGN opened at $19.80 on Friday. Legend Biotech has a 12 month low of $16.24 and a 12 month high of $37.50. The stock’s fifty day moving average price is $19.78 and its 200-day moving average price is $23.64.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. bought a new position in shares of Legend Biotech during the second quarter valued at $55,307,000. Squarepoint Ops LLC boosted its position in shares of Legend Biotech by 60.4% during the second quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock valued at $22,216,000 after buying an additional 289,772 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Legend Biotech by 44.1% during the first quarter. SG Americas Securities LLC now owns 535,658 shares of the company’s stock valued at $9,690,000 after buying an additional 163,930 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Legend Biotech by 29.5% in the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock worth $9,439,000 after buying an additional 119,000 shares in the last quarter. Finally, Candriam S.C.A. increased its holdings in Legend Biotech by 79.6% in the 1st quarter. Candriam S.C.A. now owns 470,292 shares of the company’s stock worth $8,508,000 after buying an additional 208,477 shares in the last quarter. Hedge funds and other institutional investors own 70.89% of the company’s stock.

Insider Activity at Legend Biotech

In related news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the company’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $9.46, for a total value of $258,920.20. Following the transaction, the director directly owned 52,731 shares of the company’s stock, valued at approximately $498,835.26. This represents a 34.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Carlos Santos sold 5,430 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $9.14, for a total value of $49,630.20. Following the completion of the transaction, the chief financial officer directly owned 14,246 shares in the company, valued at $130,208.44. This trade represents a 27.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.02% of the company’s stock.

More Legend Biotech News

Here are the key news stories impacting Legend Biotech this week:

Positive Sentiment: The U.S. Food and Drug Administration cleared Legend Biotech’s IND application for LB2501, an investigational in vivo CAR-T therapy for relapsed or refractory B-cell malignancies. The treatment is designed to create dual-targeting CD19/CD20 CAR-T cells inside the patient after a single infusion. The clearance supports a planned Phase 1/2 U.S. study and advances the company’s in vivo cell-engineering platform. Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501
Positive Sentiment: HC Wainwright raised its third-quarter 2026 EPS forecast for Legend Biotech to $0.02 from a projected loss of $0.02. The firm also increased its fourth-quarter estimate to $0.08 from $0.06 and maintained a Buy rating with a $65 price target. Legend Biotech analyst estimates
Positive Sentiment: HC Wainwright lifted its full-year 2026 EPS forecast to breakeven from a loss of $0.08 per share, suggesting improved expectations for Legend Biotech’s earnings trajectory. The estimate remains more optimistic than the broader current-year consensus of a $0.09 loss. Legend Biotech FY2026 earnings estimate
Negative Sentiment: Barclays cut its price target for Legend Biotech, adding a counterpoint to the positive FDA news and HC Wainwright estimate revisions. The target reduction may reflect continued concerns about valuation, execution, or the company’s path to sustained profitability. Legend Biotech Stock Price Target Cut by Barclays

Legend Biotech Company Profile

(Get Free Report)

Legend Biotech Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. Its research centers on chimeric antigen receptor T-cell (CAR-T) therapies, which use genetically modified immune cells to recognize and attack cancer cells.

The company’s leading product is Carvykti (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma.